CareDx, Inc.

CareDx, Inc. is a leading precision medicine company dedicated to improving outcomes for transplant patients and caregivers through innovative healthcare solutions. Headquartered in Brisbane, California, the company's mission is to create life-changing solutions that enable transplant patients to thrive by providing non-invasive diagnostic solutions and services across the entire transplant patient journey.

CareDx offers a comprehensive suite of products and services, primarily focused on non-invasive molecular testing for heart, kidney, and lung transplants. Key offerings include AlloSure® Kidney, a donor-derived cell-free DNA solution for kidney transplant patients, and AlloMap® Heart, a gene expression solution for heart transplant patients. The company also provides AlloSure® Heart and AlloSure® Lung, alongside digital health technologies and patient solutions designed to support care before and after transplantation.

In recent news, CareDx announced in April 2026 an agreement to divest its Lab Products business to EuroBio Scientific for $170 million, aiming to strategically focus on its core testing services and patient and digital solutions. Concurrently, the company reported strong first-quarter 2026 financial results, with a 39% year-over-year revenue growth, and raised its full-year 2026 revenue guidance. CareDx also launched VANTx™, an AI-powered cloud-native clinical data and analytics platform, and entered into an agreement to acquire Naveris, a precision oncology diagnostics company, for up to $260 million. The company is led by President and CEO John W. Hanna.